# Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-09 03:29 UTC · Category: Business · Sources: 6 · Current Velocity: 3.67

## Intelligence Brief
"Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.


Key reporting was led by WSJ, Investor's Business Daily, Reuters and Yahoo Finance. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run?
Coverage spiked when 6 independent newsrooms published 6 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| WSJ | Argenx Shares Plunge After Autoimmune-Disease Trial Halt | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNcGdaSk93bDhwRXZpVkNkWm0xaFVHX1ZHeURtdDBkai14aVFscmtkTlFVcUNGTElGTGRraUItZFJrd3pfZ20wc0RSQlU5ekJDYTRUSDNibjBuVURvd29WNWdNTUExMzlWVVRjYVNRbWpFRXRJc1dHWlZlb3lIQTFVRWJ2cDM0REdSS1pHWlJSb1NacUpuMWdZZ0xfamF4Qmxz?oc=5) |
| Investor's Business Daily | Former Highflying Biotech Hits The Skids On A Surprise Failure | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxQeUpIaVlRRUIyazhNY3M0b2h3bDM3a1JDVGhMdWhDN1ZsblZKaHA5M0t0TllPbVYyd3NDX1VuQWQ5a29SVldBZ3cwSlVDVHlfWmdjUzJRM3lUd2RnUU01X3lVdFlicjFJTWlYZXFuUTJjUjBwQkJXMEhnM3FjYk5LSmZrLXBNOVU?oc=5) |
| Reuters | Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ1VGX3BsbGNLQnZJRXBEeURjdmVpS2p0OVM2NDhpRnZMVElONjhQTnBuUHc1azFUdEJMN1JKc01IZTdiX0ZNME5sZmFYUVJVY0UtRWg5eTRyVHZBT182Z2h4LTNNOTd5cTVrWF9rTjBIVU5UWUVMWGxsZXJUVHE3XzV1WWlkYmpMUGo1MHc3WmpYc0Q4UEg0Ykl1eU5rbnRFNGZCZFlncmhGZHJicElPZXBJX3dJRVk?oc=5) |
| Yahoo Finance | Why Is ARGX Stock Plunging Today? | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQbE42LUxSY3FrTlBHSlZMVzRFR0V3bWZnd0EzUnlTMkFiay01MkN6QnZnbk1Qel9WRFoteFNBbWUtRFk3T1VhWnhHbmMwWlRRSmRVTXllWUgxV1FNQ2hBU1JWNFN5SFE2Rl9mSzVsX1NKZ1BjOUttSUZLRWlaWVhtYWVqS3NVcmpKVGt4MDNBRjF1dFcwMnFCamVB?oc=5) |
| STAT | Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxOdElDMHVUa0gzVThrS3lHYmNQZTB5V2x1RFJRR0tCbnR6R3BHVHNZOFcyT0dOcGlnb3hUQ0FWWS10bkNsLVlxQlNtQWp2N3NwZ0ZjSU1iUE9HWXlYeHJjVGh3VE5jcER6RnJ3a2lLMHBsT2tyYjB1R3BLeUxmUnJRRXpsbw?oc=5) |
| Fierce Biotech | Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run | 2026-10-08 07:03 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNWmJhclVnMm8yZHJUMkkxSnc1UmNIb1o0QlBteXRDR3hPa1ppRkNpWEI5YzFreE5yVlZlS1VFbjR1TXNnOGVxR1V6NFlycnRBZ1IwU0R3czhsRUMyOXl1WFhSQ0lPbk1xcFQ3U2lnWkozYzB0cWtUekpadUk5dEZHWTZqN2o2U3hja3UwVU1JWnlCZi1JN2RWWGttc1pPQ1k?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-09/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-run*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*